Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)

NCT04373317 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT04373317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04373317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)
Lead sponsor
VA Office of Research and Development
Phase
Phase 4
Overall status
Recruiting
Start date
October 24, 2022
Completion date
August 24, 2028
Enrollment
358 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease psychosis